Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CLAZURIL FOR SYSTEM SUITABILITY CRS (10 MG)

CLAZURIL FOR SYSTEM SUITABILITY CRS (10 MG)

101831-36-1

DISCOVER
OXALIPLATIN CRS (250 MG)

OXALIPLATIN CRS (250 MG)

61825-94-3

DISCOVER
OXALIPLATIN IMPURITY B CRS (22 MG)

OXALIPLATIN IMPURITY B CRS (22 MG)

NA

DISCOVER
OXALIPLATIN IMPURITY C CRS (20 MG)

OXALIPLATIN IMPURITY C CRS (20 MG)

NA

DISCOVER
OXALIPLATIN IMPURITY D CRS (15 MG)

OXALIPLATIN IMPURITY D CRS (15 MG)

NA

DISCOVER
DICHLORODIAMINOCYCLOHEXAN EPLATINUM CRS (15 MG)

DICHLORODIAMINOCYCLOHEXAN EPLATINUM CRS (15 MG)

NA

DISCOVER
IPRATROPIUM IMPURITY A CRS (15 MG)

IPRATROPIUM IMPURITY A CRS (15 MG)

58005-18-8

DISCOVER
Colistin sulfate 25 mg

Colistin sulfate 25 mg

1264-72-8

DISCOVER
PROPANOL - REFERENCE SPECTRUM(N/A)

PROPANOL - REFERENCE SPECTRUM(N/A)

NA

DISCOVER
TRI-N-BUTYL PHOSPHATE CRS (300 µL)

TRI-N-BUTYL PHOSPHATE CRS (300 µL)

126-73-8

DISCOVER
CHONDROITIN SULFATE SODIUM CRS (350 MG)

CHONDROITIN SULFATE SODIUM CRS (350 MG)

NA

DISCOVER
PAROXETINE HYDROCHLORIDE HEMIHYDRATE CRS (200 MG)

PAROXETINE HYDROCHLORIDE HEMIHYDRATE CRS (200 MG)

110429-35-1

DISCOVER